As part of our ongoing seminar series, the Centre of Excellence in Severe Asthma hosted Prof. Andrew Menzies-Gow, for a webinar “Optimising OCS use in severe asthma in the era of biologic agents” on 15 November 2018.
Oral corticosteroid (OCS) treatment is a mainstay add-on therapy for severe asthma. While OCS treatment has many beneficial effects, side-effects also contribute to significant disease burden. Strategies that can reduce OCS use while minimising symptoms are recommended, to limit the lifelong impacts of OCS treatment.
Prof. Menzies-Gow discusses:
Conclusions based on current data indicate:
Professor Andrew Menzies-Gow is the clinical lead for severe asthma and the director of the Lung Division at the Royal Brompton Hospital. He is a Professor of Practice (Respiratory Medicine) at Imperial College where his research interests include novel therapies for severe asthma. He was the chair of the NICE Guideline Development Group for Asthma: Diagnosis and Monitoring and is a member of the Clinical Reference Group for Specialised Adult Respiratory Medicine for NHS England leading on the commissioning of severe asthma services.
Prof. Menzie-Gow’s travel was supported by AstraZeneca
More information about severe asthma medications is also available in the Severe Asthma Toolkit – click here